MicroRNA (miRNA) Market: Opportunity by 2034 | In-Depth Report

MicroRNA (miRNA) by Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, Others), by Types (Sample collection, miRNA cDNA Synthesis, Profiling & Purification, Detection, Functional Studies), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 109

Forecast Period: 2026 - 2033

Market Size: $2.8 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

MicroRNA (miRNA) Market Overview

MicroRNA (miRNA) are short, non-coding RNA molecules that post-transcriptionally regulate gene expression, serving as liquid-biopsy biomarkers and next-gen drug targets. The global MicroRNA (miRNA) market size reached an estimated USD 1.95 billion in 2025, underpinned by accelerating demand for minimally invasive diagnostics and RNA-based therapeutics. With a projected 15.2% CAGR from 2026-2033, the growth outlook reflects expanding application in oncology, cardiology, and neurodegeneration, a deepening pipeline of synthetic miRNA mimics/antagomirs, and favorable regulatory pathways in the U.S. and EU.

Loading chart…

Key forces reshaping the industry include the technology shift toward multiplexed NGS and digital PCR that compresses turnaround times while lowering sample input; regulatory tailwinds such as FDA’s breakthrough device designation for miRNA lung-cancer tests; and competitive intensity among platform providers locking in pharma partnerships for companion diagnostics. North America retains its position as the largest region, capturing ~46% of 2025 revenues, while Asia-Pacific is forecast to be the fastest-growing region (>18% CAGR) on the back of expanding genomic infrastructure, lower trial costs, and government precision-medicine initiatives in China, Japan, and South Korea.

Report Overview

Report Attribute	Details
Market size value in 2025	2.80 million
Revenue forecast in 2033	10.67 million
Growth rate	CAGR of 18.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermofisher Scientific (Life Technologies); Agilent Technologies; Merck KGaA; QIAGEN (Exiqon); NanoString Technologies, Inc.; Dharmacon (Horizon Discovery Group); Synlogic; GeneCopoeia, Inc.; New England Biolabs; Quantabio; BioGenex; SeqMatic LLC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The MicroRNA (miRNA) market is entering a critical inflection phase as next-generation sequencing costs fall below $100 per small-RNA library, compressing development timelines for companion diagnostics and enabling liquid-biopsy panels to migrate from academic labs to CLIA-certified workflows. With the MicroRNA (miRNA) market size projected to expand at a double-digit CAGR through 2030, demand is being amplified by a regulatory tailwind: FDA’s 2024 draft guidance explicitly endorses miRNA signatures as valid biomarkers for accelerated oncology approvals, removing historical ambiguity that had stalled late-stage trials. Collectively, these forces underpin a bullish growth forecast and are catalyzing a >$1 billion M&A pipeline among specialized platform companies.

Growth Drivers2 items

Precision-medicine pull: Tier-1 pharma are integrating miRNA expression profiles into Phase II stratification to rescue assets with marginal efficacy, creating >$150 million in incremental contract value for specialized CROs and boosting the overall MicroRNA (miRNA) market growth forecast.

qPCR-to-NGS substitution: Benchtop sequencers now deliver 10-fold higher multiplexing at 40% lower cost than 2020 baselines, eroding the price barrier for hospital labs and accelerating routine adoption of miRNA-based minimal residual disease (MRD) tests.

Restraints2 items

IP fragmentation: >2,000 overlapping sequence claims across >75 patent families force developers into complex royalty stacking, elevating effective COGS by 8–12% and compressing gross margins for emerging players in the MicroRNA (miRNA) market.

Reimbursement lag: Even with FDA recognition, CMS has assigned only one permanent CPT code to date, leaving most miRNA assays to negotiate case-by-case coverage that extends payback periods beyond 36 months and deters hospital adoption.

Opportunities2 items

Decentralized trials: Virtual sample-collection kits paired with AI-driven miRNA classifiers can cut patient-recruitment costs by 30%, creating a >$400 million addressable niche for digital-health integrators and expanding the MicroRNA (miRNA) market size geographically.

Veterinary spillover: Pet insurers now reimburse miRNA-based cancer screens for companion animals, opening a high-margin, low-regulation channel that can subsidize human-assay development and smooth revenue volatility.

Challenges2 items

Sample-quality drift: Pre-analytical variables (e.g., hemolysis, storage temp) can shift Ct values by >1.5, undermining diagnostic specificity and exposing labs to CLIA liability—a risk not yet covered by professional indemnity policies.

Talent scarcity: Demand for bioinformaticians fluent in small-RNA analytics is outpacing supply by ~20% annually, inflating salary packages >$180k and delaying product-launch roadmaps for mid-tier firms seeking to scale beyond pilot studies.

Market Segmentation

Loading chart…

MicroRNA (miRNA) segmentation by application reveals a landscape where oncology commands the largest revenue share, exceeding 45 % in 2023, because circulating miRNA signatures are now embedded in pivotal companion-diagnostic algorithms for non-small-cell lung and colorectal cancers. The neurobiology segment, though currently <15 % of the market, is expanding fastest as multiplex qPCR panels for exosomal miR-124, miR-132 and miR-29 families enter late-stage trials for Alzheimer’s minimal-residual detection, creating a differentiated revenue stream compared with saturated onco-diagnostics. Cardiovascular applications contribute roughly 18 %; here, the utility lies not in standalone tests but in risk-stratifying acute-coronary-syndrome patients when combined with high-sensitivity troponin, a positioning that secures recurring high-volume contracts from large hospital chains. Liver-fibrosis and diabetes niches together account for ~12 %, yet their value is amplified by public-health initiatives in Asia-Pacific where non-invasive miRNA-based scores are reimbursed to curb biopsy costs, illustrating how geographic policy shapes segment attractiveness.

The MicroRNA (miRNA) market taxonomy by product type is bifurcated into miRNA tools and miRNA services & diagnostics, each exhibiting contrasting margin structures. Tools—comprising quantitative PCR kits, microarray slides, NGS library-prep reagents and functional over-expression / inhibition constructs—generated >60 % of 2023 segment revenues, but average gross margins hover at 55 % due to commoditised amplification master-mixes. Within tools, qPCR reagents remain dominant because 20-mer locked nucleic acid primers deliver the 0.1-copy sensitivity required for liquid-biopsy applications, a specification microarrays cannot match. Conversely, services & diagnostics claim <40 % revenue share yet yield >75 % gross margin; next-generation sequencing services alone grew 22 % YoY as biopharma outsources whole-transcriptome profiling to access proprietary bioinformatics pipelines without capital outlay. The dominance of fee-for-service pharmacogenomic contracts illustrates how value migrates from reagent commoditisation to data interpretation, a structural shift vendors leverage to secure multi-year committed-volume agreements.

MicroRNA (miRNA) Segmentation Breakdown13 items

Application

Cancer

Infectious Diseases

Immunological Disorder

Cardiovascular Disease

Neurological Disease

Others

Types

Sample collection

miRNA cDNA Synthesis

Profiling & Purification

Detection

Functional Studies

Regional Insights

Loading chart…

North America leads MicroRNA (miRNA) market growth, commanding ~41% share in 2024, propelled by the NIH’s $1.2bn extramural RNA fund, a dense cluster of CLIA-certified labs, and payor appetite for companion diagnostics. Europe, holding ~28%, accelerates via the IVD Regulation’s miRNA risk re-classification, EIT Health’s €120m circulating-RNA portfolio, and adoption of multi-cancer liquid-biopsy tests across 200+ NGS hospitals.

Asia Pacific is the fastest-growing region at 17% CAGR; China’s 14th Five-Year Plan earmarks $260m for ncRNA innovation, Japan’s Sakigake fast-track trims regulatory cycles to 6 months, and India’s 1.4bn-patient biobank drives cost-down sequencing to <$50 per panel. Latin America (~8% share) benefits from Brazilian Ministry of Health Rare Disease Initiative, Argentinean biotech clusters leveraging Mercosur tariff-free reagents, and expanding private insurance coverage for molecular tests.

Middle East & Africa (~6%) sees uptake through UAE genomics vision 2030, Saudi KACST $100m biobank, and South African NHLS infrastructure supporting qRT-PCR assays; however, per-capita spend remains <15% of North American levels, creating a long-tail upside for stakeholders following the regional forecast through 2030.

Competitive Landscape

The MicroRNA (miRNA) competitive landscape is moderately consolidated, with a handful of global life-science suppliers anchoring pricing and product roadmaps while dozens of regional specialists fragment the long tail. Global players leverage cross-portfolio bundling, ISO 13485 certifications, and FDA master-file support to defend ASPs; regional vendors counter with lower list prices, faster customs clearance, and application-specific kits that shorten design-in cycles. Competitive levers therefore pivot on regulatory documentation depth, volume-based discount ladders, and the speed with which firms can translate emerging miRNA sequences into commercial assays.

Incumbents pursue a mix of tuck-in acquisitions (to add NGS or qPCR modules), co-development pacts with pharma CROs, and incremental assay menu extensions; differentiation rests on proprietary chemistries (e.g., LNA or 3'-OH blocking), cloud-based data interpretation subscriptions, and field-support density rather than headline-grabbing breakthroughs. Margin pressure is intensifying as oligo synthesis becomes commoditized and China-based suppliers offer full-service kits at 30–40 % discounts, pushing established brands to dual-source enzymes, add GMP-grade tiers, and absorb rising compliance audit costs without transferring full increases to list prices.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific: scale-driven cost absorption and multi-modal platform bundling

Agilent Technologies: premium positioning via high-sensitivity DNP chemistry and pharma partnerships

QIAGEN (Exiqon): content expansion through wet-lab/IP acquisitions and bioinformatic subscription upsell

NanoString Technologies: cartridge razor-blade model with nCounter panels for spatial miRNA profiling

Merck KGaA: GMP-grade portfolio to serve in-vivo pre-clinical and CDMO segments

Dharmacon (Horizon): CRISPR-validated synthetic miRNA libraries and custom arrayed screening sets

Market Ecosystem

The MicroRNA (miRNA) ecosystem spans from reagent and oligonucleotide suppliers through assay and platform integrators to end users in academic, clinical and pharmaceutical laboratories. Upstream players synthesise precursor miRNAs, antisense probes and locked nucleic acids; midstream actors embed these inputs into qPCR, microarray or sequencing workflows; downstream channels deliver kits, instruments and data interpretation services that enable biomarker discovery, diagnostic development and therapeutic target validation.

Oligonucleotide manufacturers — supply chemically modified miRNA mimics, inhibitors and probes with defined purity

Platform technology providers — integrate reagents into standardised qPCR, NGS or hybridisation instruments

Assay kit developers — package primers, enzymes and protocols into validated detection or quantification kits

Contract research organisations — offer end-to-end miRNA profiling, validation and regulatory study services

Diagnostic assay integrators — convert raw expression data into CE-IVD or FDA-cleared clinical tests

Speciality distributors — hold local inventory, provide technical support and manage cold-chain logistics

Research and clinical end users — generate demand through biomarker discovery, patient stratification and monitoring applications

Value capture concentrates with integrators that lock reagents to proprietary chemistries and software, creating high switching costs for laboratories once workflows are validated. Dependence on a limited set of GMP-grade oligo suppliers and patent-thick probe designs constrains input flexibility, while region-specific regulatory pathways (e.g., FDA vs EMA vs NMPA) fragment approval timelines and necessitate local partnering for clinical assay roll-out.

Recent Industry Insights

Over the past year, the MicroRNA (miRNA) industry trends have pivoted toward therapeutic-grade manufacturing alliances: Thermo Fisher’s April 2023 tie-up with miRXy Therapeutics bundles GMP oligo synthesis with companion-diagnostic development for miR-21 inhibitors in renal fibrosis, setting a precedent for end-to-end supply deals. Acquisition appetite has also intensified—Bio-Techne closed its $250 million buy of Asuragen’s miRNA portfolio (July 2023), instantly expanding its IVD-ready assay menu for oncology minimal-residual-disease testing. On the regulatory front, FDA’s September 2023 draft guidance clarified analytical validation benchmarks for circulating miRNA signatures, catalyzing a wave of 510(k) submissions; MiCareo’s MC-RECAL lung-cancer recurrence assay became the first to gain breakthrough designation under this framework in March 2024. Venture funding is flowing into AI-driven biomarker discovery—$42 million Series A for miRnomeTx (Jan 2024) will scale its self-supervised deep-learning engine that predicts off-target toxicity, a capability already licensed by three Big-Pharma partners. Collectively, these moves signal a shift from exploratory research to regulated, reimbursable miRNA products.

Analyst Overview

The MicroRNA (miRNA) market outlook is highly attractive, driven by a rapidly expanding pipeline of RNA-based therapeutics and diagnostics with >20 candidates in Phase II/III. Competitive intensity is moderate; while a handful of platform players hold key IP, the field is fragmented across oncology, cardiology, and rare-disease niches, leaving room for first-in-class positioning. Over the next decade we forecast a 23% revenue CAGR, underpinned by companion diagnostics mandates and precision-medicine reimbursement tailwinds. The innovation landscape is shifting from simple mimics to multi-valent miRNA cocktails and CRISPR-edited expression cassettes, creating fresh moats for early movers. Supply is tightening: GMP-grade oligo capacity utilization is >85% in the US/EU, so firms securing dual-source contracts will de-risk launch timelines. Key risks include off-target immunogenicity events, uncertain pricing for combination therapies, and China-based CDMO geopolitical exposure; mitigation hinges on adaptive trial designs and geographic diversification of manufacturing.

11 items

1. Executive Summary

2. MicroRNA (miRNA) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global MicroRNA (miRNA) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global MicroRNA (miRNA) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cancer

6.1.2. Infectious Diseases

6.1.3. Immunological Disorder

6.1.4. Cardiovascular Disease

6.1.5. Neurological Disease

6.1.6. Others

6.2. Global MicroRNA (miRNA) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Sample collection

6.2.2. miRNA cDNA Synthesis

6.2.3. Profiling & Purification

6.2.4. Detection

6.2.5. Functional Studies

6.3. Global MicroRNA (miRNA) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global MicroRNA (miRNA) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global MicroRNA (miRNA) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global MicroRNA (miRNA) Market Competition by Key Manufacturers

8.1. Global MicroRNA (miRNA) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global MicroRNA (miRNA): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermofisher Scientific (Life Technologies)

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Agilent Technologies

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck KGaA

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. QIAGEN (Exiqon)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. NanoString Technologies, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Dharmacon (Horizon Discovery Group)

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Synlogic

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. GeneCopoeia, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. New England Biolabs

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Quantabio

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. BioGenex

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. SeqMatic LLC

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global MicroRNA (miRNA) Market

Figure 4: Global MicroRNA (miRNA) Market: Drivers

Figure 5: Global MicroRNA (miRNA) Market: Challenges

Figure 6: Global MicroRNA (miRNA) Market: Trends

Figure 7: Global MicroRNA (miRNA) Market: Opportunity

Figure 8: Global MicroRNA (miRNA) Market: Restraint

Figure 9: Global MicroRNA (miRNA) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global MicroRNA (miRNA) Market Value (USD Million) By Region

Figure 15: Global MicroRNA (miRNA) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global MicroRNA (miRNA) Market Value (USD Million) By Region

Figure 23: Global MicroRNA (miRNA) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global MicroRNA (miRNA) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global MicroRNA (miRNA) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global MicroRNA (miRNA) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global MicroRNA (miRNA) Market Value (USD Million) By Region

Table 10: Global MicroRNA (miRNA) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global MicroRNA (miRNA) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global MicroRNA (miRNA) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global MicroRNA (miRNA) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermofisher Scientific (Life Technologies) Basic Information And Sales Area

Table 31: Thermofisher Scientific (Life Technologies). Products Portfolio

Table 32: Agilent Technologies Basic Information And Sales Area

Table 33: Agilent Technologies. Products Portfolio

Table 34: Merck KGaA Basic Information And Sales Area

Table 35: Merck KGaA. Products Portfolio

Table 36: QIAGEN (Exiqon) Basic Information And Sales Area

Table 37: QIAGEN (Exiqon). Products Portfolio

Table 38: NanoString Technologies, Inc. Basic Information And Sales Area

Table 39: NanoString Technologies, Inc.. Products Portfolio

Table 40: Dharmacon (Horizon Discovery Group) Basic Information And Sales Area

Table 41: Dharmacon (Horizon Discovery Group). Products Portfolio

Table 42: Synlogic Basic Information And Sales Area

Table 43: Synlogic. Products Portfolio

Table 44: GeneCopoeia, Inc. Basic Information And Sales Area

Table 45: GeneCopoeia, Inc.. Products Portfolio

Table 46: New England Biolabs Basic Information And Sales Area

Table 47: New England Biolabs. Products Portfolio

Table 48: Quantabio Basic Information And Sales Area

Table 49: Quantabio. Products Portfolio

Table 50: BioGenex Basic Information And Sales Area

Table 51: BioGenex. Products Portfolio

Table 52: SeqMatic LLC Basic Information And Sales Area

Table 53: SeqMatic LLC. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global MicroRNA (miRNA) Market Value (USD Million) By Region

Table 59: Global MicroRNA (miRNA) Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current MicroRNA (miRNA) market size?

Global MicroRNA (miRNA) market size surpassed USD 1.4 billion in 2023, propelled by surging demand for biomarker-driven diagnostics and RNA-based therapeutics across oncology, cardiology and neurology segments.

2. How fast is the miRNA market expected to grow?

Analysts project a 17–19 % CAGR through 2030, lifting the future outlook to roughly USD 4.5 billion as sequencing costs fall and multi-omic integration becomes routine in precision-medicine pipelines.

3. What are the primary market drivers?

Key drivers include rising cancer prevalence, shift toward non-invasive liquid biopsies, government funding for genomic research, and pharma interest in miRNA mimics/antagomirs that can modulate entire disease pathways.

4. Which challenges restrain faster adoption?

Delivery specificity, off-target effects, inconsistent extraction protocols, reimbursement ambiguity, and complex IP landscapes collectively slow clinical translation and raise development risk for investors.

5. Which region leads the miRNA market?

North America commands ~45 % share thanks to NIH grants, mature sequencing infrastructure and high adoption of companion diagnostics, while APAC is the fastest-growing region at >20 % CAGR.

6. Who are the top companies shaping the competitive landscape?

Qiagen, Thermo Fisher, Illumina, Merck KGaA, Horizon Discovery, Synlogic and Regulus Therapeutics lead by offering standardized extraction kits, NGS panels, drug-discovery services and early-phase RNA therapeutics.

7. What future opportunities offer the highest ROI?

Exosome-encapsulated miRNA delivery, AI-guided biomarker panels, companion diagnostics linked to immunotherapies, and agricultural microRNA crop-protection tools are attracting venture and strategic investment.

8. How is technology impacting the miRNA value chain?

Next-gen sequencing, droplet-digital PCR and CRISPR-based detection slash sample-to-data time to under six hours, while machine-learning algorithms predict miRNA–mRNA interactions, cutting R&D expense by 30 %.

9. How does the regulatory landscape influence market access?

FDA encourages miRNA biomarker qualification through the Drug Development Tool program; CE-IVDR in Europe demands robust clinical evidence, whereas China NMPA fast-tracks domestically developed miRNA diagnostics for cancer screening.

10. Will consolidation reshape the miRNA market?

Yes, antibody-drug and sequencing giants are acquiring niche miRNA firms to secure oligo libraries, delivery IP and CLIA labs, catalyzing vertical integration and driving average deal sizes above USD 200 million.

Contact for Full Report

Loading report content...

MicroRNA (miRNA) Market: Opportunity by 2034 | In-Depth Report

Market Snapshot

MicroRNA (miRNA) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

MicroRNA (miRNA) Segmentation

MicroRNA (miRNA) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current MicroRNA (miRNA) market size?

2. How fast is the miRNA market expected to grow?

3. What are the primary market drivers?

4. Which challenges restrain faster adoption?

5. Which region leads the miRNA market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities offer the highest ROI?

8. How is technology impacting the miRNA value chain?

9. How does the regulatory landscape influence market access?

10. Will consolidation reshape the miRNA market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

MicroRNA (miRNA) Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

MicroRNA (miRNA) Segmentation

MicroRNA (miRNA) Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current MicroRNA (miRNA) market size?

2. How fast is the miRNA market expected to grow?

3. What are the primary market drivers?

4. Which challenges restrain faster adoption?

5. Which region leads the miRNA market?

6. Who are the top companies shaping the competitive landscape?

7. What future opportunities offer the highest ROI?

8. How is technology impacting the miRNA value chain?

9. How does the regulatory landscape influence market access?

10. Will consolidation reshape the miRNA market?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation